PROK
What one share of ProKidney holds
Biological Products, (No Diagnostic Substances)
We are a late-clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advanced chronic kidney disease (“CKD”) and diabetes.
ProKidney’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.01 |
|---|---|
| Profit | −$0.55 |
| Capex (buildings and equipment) | $0.12 |
| Free cash flow | −$1.05 |
| Cash and investments | $0.40 |
| Book value | −$4.66 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | $0.00 | −$0.57 | $0.55 | −$2.00 | — | −$17.73 |
| 2024 | $0.00 | −$0.62 | $0.30 | −$1.58 | — | −$10.08 |
| 2025 | $0.01 | −$0.52 | $0.11 | −$1.02 | — | −$7.62 |